top of page
News
Search
“Pharmadeals more and more dependent on regulatory due diligence”
Dutch version: https://mena.nl/artikel/hanneke-later-nijland-genome-lawyers-farmadeals-regulatory-due-diligence/ By: Jan Bletz 29 October 2025 In the heavily regulated pharma market, buyers face greater risks. Regulatory due diligence offers a solution. · Geopolitical shifts increase risks in the pharma sector: The US is closing itself off and implementing protectionist measures, China is developing into an innovative biotech power, and Europe remains fragmented with
Oct 305 min read
Van Amsterdam en Brussel tot China: wat wij zien gebeuren in de farmaceutische wereld
In samenwerking met: Yilmaz Biter, BioPitch Hanneke Later-Nijland, advocaat-partner bij Genome Lawyers en oprichter van The Genotype...
Jul 78 min read
The Genotype Network expands to Switzerland with Annemarie Lagger
Annemarie Lagger We are pleased to welcome a new member to our network: Annemarie Lagger from Walder Wyss! Annemarie has extensive...
Jun 271 min read
Chambers ranking update 2025
We are pleased to announce that Hanneke Later-Nijland has received an esteemed recognition in the 2025 Chambers rankings. Key Highlights...
Jun 201 min read
Save-the-date: The Genotype Network Conference 26 September 2025
Join us on September 26th in Amsterdam for The Genotype Network (TGN) conference in Amsterdam. We'll delve into "The impact of...
Jun 151 min read
bottom of page